Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.

Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
Br J Dermatol. 2020 May 14;:
Authors: Dangien A, Ram-Wolff C, Brice P, Battistella M, Roelens M, Moins-Teisserenc H, de Latour RP, Mourah S, Bouaziz JD, Lebbé C, Bagot M, de Masson A
Abstract
Ifosfamide + etoposide (I+E) have been used to treat lymphomas, combined with platinum-based agents in Hodgkin disease or non-Hodgkin lymphomas including peripheral T-cell lymphomas. Monoclonal antibodies have induced long-term remissions in CTCL but are usually poorly effective in transformed disease. Allogeneic hematopoietic stem cell transplantation (alloHSCT) holds a potential for cure but relies on the existence of a pre-transplant CR which may require the use of chemotherapeutic regimens.
PMID: 32407544 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - May 13, 2020 Category: Dermatology Authors: Dangien A, Ram-Wolff C, Brice P, Battistella M, Roelens M, Moins-Teisserenc H, de Latour RP, Mourah S, Bouaziz JD, Lebbé C, Bagot M, de Masson A Tags: Br J Dermatol Source Type: research